AM Squared Ltd Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

AM Squared Ltd bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, HoldingsChannel reports. The fund bought 900 shares of the company’s stock, valued at approximately $104,000.

Other institutional investors have also added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences in the second quarter valued at $28,000. Innealta Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter valued at about $30,000. New Covenant Trust Company N.A. bought a new position in shares of Neurocrine Biosciences during the first quarter valued at about $32,000. EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter valued at about $35,000. Finally, Blue Trust Inc. grew its stake in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NBIX. Raymond James reaffirmed an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Royal Bank of Canada reduced their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. JPMorgan Chase & Co. raised their price objective on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Finally, BMO Capital Markets cut their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $117.44 on Friday. The firm has a 50 day moving average price of $118.50 and a 200-day moving average price of $132.66. Neurocrine Biosciences, Inc. has a 52-week low of $107.84 and a 52-week high of $157.98. The firm has a market capitalization of $11.89 billion, a price-to-earnings ratio of 31.49 and a beta of 0.35.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.